title: Prognostic significance of adenosine deaminase in children with malignancies.
abstract: In 33 children, 23 with acute lymphoblastic leukemia (ALL) and 10 with solid tumors, the phenotype of the enzyme adenosine deaminase (ADA) was detected in the erythrocytes by electrophoresis in cellulose acetate. In all children the ADA enzyme activity was also determined in the plasma by spectrophotometry at the onset of the disease, during remission, at the end of the therapy, and during relapse. The phenotype in all children was ADA1-1. There was a difference in enzyme activity between the mean values of children with ALI and those with solid tumors. There were also differences among the subtypes of ALL and also among the stages of ALL and the stages of solid tumors. In 23 children with ALL the mean value (MV) and the corresponding standard error (SEM) of enzyme activity at the onset of the disease were MV +/- SEM = 60.2 +/- 6.2 IU/L. This was higher than that of the control group (control group: MV +/- SEM = 27.8 +/- 3.3 IU/L). During remission the enzyme activity was lower than that of the control group (MV +/- SEM = 19.6 +/- 1.7 IU/L); at the end of the therapy it was MV +/- SEM = 24.0 +/- 1.3 IU/L, which is close to that of the control group; and during relapse it was much higher compared with the control group (MV +/- SEM = 73.1 +/- 4.6 IU/L). These values are discussed in connection to the leukaemic subtypes. In 10 children with solid tumors the mean value of enzyme activity at the onset of the disease was MV +/- SEM = 48.8 +/- 2.4 IU/L. During therapy it was MV +/- SEM = 32.4 +/- 1.9 IU/L and at the end of therapy MV +/- SEM = 22.1 +/- 2.5 IU/L. The aim of this work is to study the qualitative isoenzyme abnormalities to better understand the biological nature of the malignancies, to distinguish main groups and subsets of ALL and solid tumors on an enzymatic basis, and to identify possible sensitive key enzymes as targets for chemotherapy.
authors.affiliation: 2nd Department of Paediatrics, Aristotle University of Thessaloniki, Greece.
authors.forename: M
authors.initials: M
authors.lastname: Hatzistilianou
authors.forename: F
authors.initials: F
authors.lastname: Athanassiadou
authors.forename: D
authors.initials: D
authors.lastname: Catriu
authors.forename: A
authors.initials: A
authors.lastname: Makedou
authors.forename: S
authors.initials: S
authors.lastname: Hitoglou
authors.forename: A
authors.initials: A
authors.lastname: Papaeconomou
mesh_terms: D000243:Adenosine Deaminase / Q000097:blood*; D000293:Adolescent; D000704:Analysis of Variance; D014408:Biomarkers, Tumor / Q000097:blood*; D002648:Child; D002675:Child, Preschool; D004912:Erythrocytes / Q000201:enzymology*; D006801:Humans; D007223:Infant; D009369:Neoplasms / Q000097:blood* / Q000201:enzymology / Q000628:therapy; D010641:Phenotype; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000097:blood* / Q000201:enzymology / Q000628:therapy; D011379:Prognosis; D012016:Reference Values
chemical_list: D014408:Biomarkers, Tumor; D000243:Adenosine Deaminase